August 2012
-
Inhaled drug developer Savara Pharmaceuticals has announced the appointment of former Edgemont Pharmaceuticals CFO David L. Lowrance as its new Chief Financial Officer. Savara cited Lowrance’s experience leading IPOs for Acucela, where he was CFO… Read more . . .
-
Arch Biopartners has announced that Dr. Ralph Panos of the Cincinnati Veterans Affairs Medical Center (CVAMC) will prepare a protocol for human trials of the company’s AB569 inhaled bactericide and will subsequently prepare an application… Read more . . .
-
Upsher-Smith Laboratories has presented data from a Phase 1 study of its USL261 midazolam nasal spray in children with epilepsy demonstrating that the median Tmax for 1.25 mg, 2.5 mg and 5 mg single doses… Read more . . .
-
Fierce Pharma has published a copy of a citizen petition filed by Sandoz that challenges the FDA’s recommendations for establishing bioequivalence for generic copies of Advair Diskus 100/50. The FDA published the draft guidance for… Read more . . .
-
A new animation from Copley Scientific shows how the standard compendial set-up for cascade impaction can be enhanced to ensure that data generated in the lab (in vitro) is as representative as possible of what… Read more . . .
-
The 27th Drug Delivery to the Lungs (DDL) meeting expects a record number of delegates and exhibitors when the meeting returns to the Edinburgh International Conference Centre December 7-9. And, organizers say, being able to… Read more . . .
-
Windtree Therapeutics has announced that a lung deposition study in cynomolgus macaques showed that its proprietary aerosol delivery system (ADS) delivered KL4 surfactant uniformly to all regions of the lung. The ADS is being developed… Read more . . .
-
Eurocine Vaccines has started a Phase 1/2 clinical study of its Immunose FLU intranasal quadrivalent influenza vaccine, which uses the company’s Endocine adjuvent and inactivated split antigens, the company said. Results should be available in… Read more . . .
-
The FDA’s Bone, Reproductive and Urologic Drugs Advisory Committee (BRUDAC) has voted to recommend approval of Allergan’s SER120 desmopressin nasal spray for the treatment of nocturia (needing to wake up to urinate at night) in… Read more . . .
-
The US Patent and Trademark Office (USPTO) has granted SmartInhaler maker Adherium Limited US Patent No. 9,468,729, titled “Releasable monitor with optical dose counter for a medicament inhaler, the company announced, saying that, “This patent… Read more . . .
Featured event:
5th Annual Inhaled & Nasal Biologics | DNA Forum
5th Annual Inhaled & Nasal Biologics | DNA Forum
24th-25th September 2026, Cambridge, UK
Join us for a ground-breaking and insightful forum: Two days of cutting-edge talks and networking opportunities in this complex area of drug and vaccine development.
With renowned industry leaders who will share their insights and real-world case studies, our speakers will explore innovative formulation and delivery technologies and the rationale behind overcoming development challenges. Don’t miss out on this opportunity to learn more about key topics shaping the future of inhaled therapeutics.
Get online to see speakers announced so far. Registration is live – save your seat now!
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
October 19-October 20: MVIC Autumn Training 2026, Lund, Sweden
October 21-October 22: MVIC Symposium, Lund, Sweden
November 10-November 11: Rescon Europe 2026, Porto, Portugal
December 9-December 11: DDL 2026, Edinburgh, Scotland